Â鶹ԭ´´

1 EXECUTIVE SUMMARY 19
2 INTRODUCTION 24
2.1 KEY TAKEAWAYS 24
2.2 SCOPE OF THE REPORT 25
2.3 REPORT DESCRIPTION 25
2.4 MARKETS COVERED 26
2.5 STAKEHOLDERS 28
2.6 RESEARCH METHODOLOGY 28
2.6.1 MARKET SIZE ESTIMATION 29
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.6.3 SECONDARY SOURCES 33
2.6.4 PRIMARY SOURCES 34
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 34
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 35
2.6.7 ASSUMPTIONS 36
3 MARKET ANALYSIS 37
3.1 INTRODUCTION 37
3.2 MARKET SEGMENTATION 38
3.3 FACTORS INFLUENCING MARKET 40
3.3.1 DRIVERS AND OPPORTUNITIES 41
3.3.1.1 Increasing demand for surgical procedures boosts surgical sealants andÌý
adhesives market growth 41
3.3.1.2 Emergence of technically advanced products 41
3.3.1.3 Acquisition to open an array of opportunities for the market to flourish 42
3.3.1.4 Increasing geriatric population 43
3.3.1.5 Acceptance of surgical sealants and adhesives and market expansion inÌý
emerging nations 43
3.3.2 RESTRAINTS AND THREATS 44
3.3.2.1 Pitfalls in usage of surgical sealants and adhesives 44
3.3.2.2 Expensive surgical sealants and adhesives impeding effective penetrationÌý
in low and middle income countries 44
3.3.2.3 Unfavorable reimbursement policies in developing nations 45
3.3.2.4 Stringent regulatory guidelines 45
3.3.2.5 Availability of alternative products 46
3.4 REGULATORY AFFAIRS 47
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 47
3.4.1.1 ISO 9001: 2015 quality management system 47
3.4.1.2 ISO 14644-1 clean room standards 47
3.4.1.3 ISO 13485 medical devices 48
3.4.1.4 ISO 10993 biological evaluation of medical devices 48
3.4.2 ASTM INTERNATIONAL STANDARDS 48
3.4.3 U.S. 49
3.4.4 CANADA 50
3.4.5 EUROPE 50
3.4.6 JAPAN 50
3.4.7 CHINA 51
3.4.8 INDIA 52
3.5 CLINICAL TRIALS 53
3.6 PORTER’S FIVE FORCE ANALYSIS 57
3.6.1 THREAT OF NEW ENTRANTS 58
3.6.2 THREAT OF SUBSTITUTES 58
3.6.3 BARGAINING POWER OF SUPPLIERS 59
3.6.4 BARGAINING POWER OF BUYERS 59
3.6.5 RIVALRY AMONG EXISTING COMPETITORS 60
3.7 SUPPLY CHAIN ANALYSIS 61
3.8 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 65
3.9 SURGICAL SEALANTS AND ADHESIVES COMPANY COMPARISON BYÌý
PRODUCT TYPE, MATERIAL, PRODUCT NAME AND APPLICATIONS 68
3.10 MARKET PENETRATION OF SURGICAL SEALANTS AND ADHESIVES INÌý
SURGICAL WOUND CLOSURE MARKET 79
4 ÌýSURGICAL SEALANTS AND ADHESIVES GLOBAL MARKET, BY PRODUCT 81
4.1 INTRODUCTION 81
4.2 NATURAL SURGICAL SEALANTS AND ADHESIVES 84
4.2.1 FIBRIN 89
4.2.2 COLLAGEN 92
4.2.3 GELATIN 95
4.2.4 ALBUMIN 98
4.2.5 OTHERS 101
4.3 SYNTHETIC SURGICAL SEALANTS AND ADHESIVES 104
4.3.1 CYANOACRYLATE 109
4.3.2 HYDROGEL 111
4.3.3 OTHERS 115
5 SURGICAL SEALANTS AND ADHESIVES GLOBAL MARKET, Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý ÌýBY APPLICATION 118
5.1 INTRODUCTION 118
5.2 CARDIOVASCULAR SURGERY 121
5.3 GENERAL SURGERY 124
5.4 ORTHOPAEDIC SURGERY 127
5.5 UROLOGY 130
5.6 PULMONOLOGY 133
5.7 NEUROSURGERY 136
5.8 GYNAECOLOGY 139
5.9 COSMETIC SURGERY 142
5.10 OTHERS 145
6 SURGICAL SEALANTS AND ADHESIVES GLOBAL MARKET, Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý Ìý ÌýBY END-USERS 148
6.1 INTRODUCTION 148
6.2 HOSPITALS 151
6.3 AMBULATORY SURGICAL CENTERS 154
6.4 OTHERS 157
7 REGIONAL ANALYSIS 160
7.1 INTRODUCTION 160
7.2 NORTH AMERICA 163
7.2.1 U.S. 172
7.2.2 OTHERS 175
7.3 EUROPE 178
7.3.1 GERMANY 187
7.3.2 U.K. 190
7.3.3 FRANCE 193
7.3.4 OTHERS 196
7.4 APAC 199
7.4.1 JAPAN 208
7.4.2 CHINA 211
7.4.3 INDIA 214
7.4.4 OTHERS 217
7.5 ROW 220
7.5.1 BRAZIL 229
7.5.2 REST OF LATIN AMERICA 232
7.5.3 MIDDLE EAST AND OTHERS 235
8 COMPETITIVE LANDSCAPE 238
8.1 INTRODUCTION 238
8.2 APPROVALS 239
8.3 AGREEMENT 241
8.4 ACQUISITIONS 243
8.5 NEW PRODUCT LAUNCH 244
8.6 OTHER DEVELOPMENTS 245
9 MAJOR COMPANIES 246
9.1 ADVANCED MEDICAL SOLUTIONS GROUP PLC 246
9.1.1 OVERVIEW 246
9.1.2 FINANCIALS 247
9.1.3 PRODUCT PORTFOLIO 250
9.1.4 KEY DEVELOPMENTS 250
9.1.5 BUSINESS STRATEGY 250
9.1.6 SWOT ANALYSIS 251
9.2 BAXTER INTERNATIONAL, INC 252
9.2.1 OVERVIEW 252
9.2.2 FINANCIALS 253
9.2.3 PRODUCT PORTFOLIO 256
9.2.4 KEY DEVELOPMENTS 256
9.2.5 BUSINESS STRATEGY 257
9.2.6 SWOT ANALYSIS 258
9.3 B.BRAUN MELSUNGEN AG 259
9.3.1 OVERVIEW 259
9.3.2 FINANCIALS 260
9.3.3 PRODUCT PORTFOLIO 263
9.3.4 KEY DEVELOPMENTS 263
9.3.5 BUSINESS STRATEGY 263
9.3.6 SWOT ANALYSIS 264
9.4 BECTON, DICKINSON AND COMPANY (C.R.BARD INC.) 265
9.4.1 OVERVIEW 265
9.4.2 FINANCIALS* 266
9.4.3 PRODUCT PORTFOLIO 269
9.4.4 KEY DEVELOPMENTS 269
9.4.5 BUSINESS STRATEGY 270
9.4.6 SWOT ANALYSIS 271
9.5 COHERA MEDICAL, INC. 272
9.5.1 OVERVIEW 272
9.5.2 FINANCIALS 272
9.5.3 PRODUCT PORTFOLIO 272
9.5.4 KEY DEVELOPMENTS 273
9.5.5 BUSINESS STRATEGY 274
9.5.6 SWOT ANALYSIS 275
9.6 CRYOLIFE, INC. 276
9.6.1 OVERVIEW 276
9.6.2 FINANCIALS 277
9.6.3 PRODUCT PORTFOLIO 280
9.6.4 KEY DEVELOPMENTS 280
9.6.5 BUSINESS STRATEGY 282
9.6.6 SWOT ANALYSIS 283
9.7 JOHNSON & JOHNSON (ETHICON) 284
9.7.1 OVERVIEW 284
9.7.2 FINANCIALS 285
9.7.3 PRODUCT PORTFOLIO 289
9.7.4 KEY DEVELOPMENTS 289
9.7.5 BUSINESS STRATEGY 290
9.7.6 SWOT ANALYSIS 291
9.8 MALLINCKRODT PLC 292
9.8.1 OVERVIEW 292
9.8.2 FINANCIALS 293
9.8.3 PRODUCT PORTFOLIO 296
9.8.4 KEY DEVELOPMENTS 296
9.8.5 BUSINESS STRATEGY 297
9.8.6 SWOT ANALYSIS 298
9.9 MEDTRONIC PLC 299
9.9.1 OVERVIEW 299
9.9.2 FINANCIALS 300
9.9.3 PRODUCT PORTFOLIO 302
9.9.4 KEY DEVELOPMENTS 303
9.9.5 BUSINESS STRATEGY 303
9.9.6 SWOT ANALYSIS 304
9.10 TAKEDA PHARMACEUTICAL COMPANY LTD. 305
9.10.1 OVERVIEW 305
9.10.2 FINANCIALS 306
9.10.3 PRODUCT PORTFOLIO 306
9.10.4 KEY DEVELOPMENTS 307
9.10.5 BUSINESS STRATEGY 307
9.10.6 SWOT ANALYSIS 308